Mithra Partner Mayne shows steady Nextstellis growth in FY23
Mithra's commercial partner for Nextstellis in the US, Mayne Pharma, announced its FY23 financial results (July '22 – June '23). The company conducted an extensive repositioning, and made steady progress on the commercialisation of Nextstellis. The commercial ramp-up in the key US market appears in line with our expectations, hence we maintain our FY23 estimates for Mithra. € 2.5 TP and Hold rating reiterated.Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.